This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yezhelyev, M. V. Articles by Bruns, C. J. Search for Related Content PubMed PubMed Citation Articles by Yezhelyev, M. V. Articles by Bruns, C. J.

Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice

¹ Department of Surgery, University of Munich-Grosshadern, Munich, Germany; ² Department of Surgery, University of Regensburg, Regensburg, Germany; ³ Institute of Pathology, University of Erlangen, Erlangen, Germany; and ⁴ AstraZeneca, Macclesfield, United Kingdom

Purpose: The Src family comprises a family of nonreceptor intracellular tyrosine kinases that mediate a variety of cellular pathways. Src kinases are overexpressed in a variety of human tumors, including cancer of the colon, breast, and pancreas, and they are an integral part of tumor cell signaling pathways associated with migration, proliferation, adhesion, and angiogenesis.

Experimental Design: We investigated whether the blockade of Src kinase by daily oral administration of the novel Src tyrosine kinase inhibitor AZM475271 [kindly provided by AstraZeneca (Macclesfield, United Kingdom)], alone or in combination with intraperitoneal gemcitabine, can inhibit growth and metastasis of orthotopically implanted human pancreatic carcinoma cells in nude mice.

Results: Treatment with AZM475271 alone reduced the primary pancreatic tumor volume by approximately 40%, whereas AZM475271 plus gemcitabine reduced tumor volume by 90%. Furthermore, treatment with AZM475271 and gemcitabine significantly reduced metastasis: none of eight animals who received the combination treatment had lymph node or liver metastases, compared with five of five and three of five animals, respectively, in the control group (P = 0.001). Src inhibition by AZM475271 (alone or with gemcitabine) was associated with significantly reduced tumor cell proliferation, decreased tumor microvessel density, and increased apoptosis in vivo. Moreover, these effects were all significantly increased when gemcitabine was combined with AZM475271 compared with gemcitabine alone.

Conclusions: Src inhibition by AZM475271, either alone or in combination with gemcitabine, demonstrated significant antitumor and antimetastatic activity in an orthotopic nude mouse model for human pancreatic cancer. The combination of AZM475271 with gemcitabine sensitized tumor cells to the cytotoxic effect of gemcitabine.

This article has been cited by other articles:

				P. Koppikar, S.-H. Choi, A. M. Egloff, Q. Cai, S. Suzuki, M. Freilino, H. Nozawa, S. M. Thomas, W. E. Gooding, J. M. Siegfried, et al. Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., July 1, 2008; 14(13): 4284 - 4291. [Abstract] [Full Text] [PDF]

				S. Kopetz, A. N. Shah, and G. E. Gallick Src Continues Aging: Current and Future Clinical Directions Clin. Cancer Res., December 15, 2007; 13(24): 7232 - 7236. [Abstract] [Full Text] [PDF]

				L. C. DeRosier, S. M. Vickers, K. R. Zinn, Z. Huang, W. Wang, W. E. Grizzle, J. Sellers, C. R. Stockard Jr., T. Zhou, P. G. Oliver, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth Mol. Cancer Ther., December 1, 2007; 6(12): 3198 - 3207. [Abstract] [Full Text] [PDF]

				M. Vidal, S. Warner, R. Read, and R. L. Cagan Differing Src Signaling Levels Have Distinct Outcomes in Drosophila Cancer Res., November 1, 2007; 67(21): 10278 - 10285. [Abstract] [Full Text] [PDF]

				K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				A. S. Tsao, D. He, B. Saigal, S. Liu, J. J. Lee, S. Bakkannagari, N. G. Ordonez, W. K. Hong, I. Wistuba, and F. M. Johnson Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol. Cancer Ther., July 1, 2007; 6(7): 1962 - 1972. [Abstract] [Full Text] [PDF]

				D. Mahadevan and D. D. Von Hoff Tumor-stroma interactions in pancreatic ductal adenocarcinoma Mol. Cancer Ther., April 1, 2007; 6(4): 1186 - 1197. [Abstract] [Full Text] [PDF]

				A. Di Florio, G. Capurso, M. Milione, F. Panzuto, R. Geremia, G. D. Fave, and C. Sette Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells Endocr. Relat. Cancer, March 1, 2007; 14(1): 111 - 124. [Abstract] [Full Text] [PDF]

				H. Jallal, M.-L. Valentino, G. Chen, F. Boschelli, S. Ali, and S. A. Rabbani A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis In vitro and In vivo Cancer Res., February 15, 2007; 67(4): 1580 - 1588. [Abstract] [Full Text] [PDF]

				D. Okutani, M. Lodyga, B. Han, and M. Liu Src protein tyrosine kinase family and acute inflammatory responses Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L129 - L141. [Abstract] [Full Text] [PDF]

				N. Rucci, I. Recchia, A. Angelucci, M. Alamanou, A. Del Fattore, D. Fortunati, M. Susa, D. Fabbro, M. Bologna, and A. Teti Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 161 - 172. [Abstract] [Full Text] [PDF]

				G Capurso, S Lattimore, T Crnogorac-Jurcevic, F Panzuto, M Milione, V Bhakta, N Campanini, S M Swift, C Bordi, G D. Fave, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer, June 1, 2006; 13(2): 541 - 558. [Abstract] [Full Text] [PDF]

				J. G. Trevino, J. M. Summy, D. P. Lesslie, N. U. Parikh, D. S. Hong, F. Y. Lee, N. J. Donato, J. L. Abbruzzese, C. H. Baker, and G. E. Gallick Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model Am. J. Pathol., March 1, 2006; 168(3): 962 - 972. [Abstract] [Full Text] [PDF]

				J. M. Summy, J. G. Trevino, D. P. Lesslie, C. H. Baker, W. C. Shakespeare, Y. Wang, R. Sundaramoorthi, C. A. Metcalf III, J. A. Keats, T. K. Sawyer, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes Mol. Cancer Ther., December 1, 2005; 4(12): 1900 - 1911. [Abstract] [Full Text] [PDF]

				J. G. Trevino, J. M. Summy, M. J. Gray, M. B. Nilsson, D. P. Lesslie, C. H. Baker, and G. E. Gallick Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis Cancer Res., August 15, 2005; 65(16): 7214 - 7222. [Abstract] [Full Text] [PDF]

				A. A. Adjei and M. Hidalgo Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy J. Clin. Oncol., August 10, 2005; 23(23): 5386 - 5403. [Abstract] [Full Text] [PDF]

				A E Wakeling Inhibitors of growth factor signalling Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S183 - S187. [Abstract] [Full Text] [PDF]

				J. M. Golas, J. Lucas, C. Etienne, J. Golas, C. Discafani, L. Sridharan, E. Boghaert, K. Arndt, F. Ye, D. H. Boschelli, et al. SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models Cancer Res., June 15, 2005; 65(12): 5358 - 5364. [Abstract] [Full Text] [PDF]